Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Some big deals in the second quarter have raised hopes that takeouts are back.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Adverse events will be closely watched when full data are reported.
